Semax
Heptapeptide analog of ACTH(4–10) studied for effects on focus, BDNF expression, and stress resilience.
This compound was removed from FDA Category 2 in 2026, but final action on the 503A compounding list is still pending. Allora does not currently dispense it — join the waitlist and we will notify you if it becomes available through our licensed pharmacy partners.
Mechanism of action
How Semax works
Modulates dopamine and serotonin signaling and influences expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
Areas of study
What Semax is studied for
- check
Focus and attention support
- check
Cognitive recovery after high-stress periods
- check
Adjunctive use in neuro-resilience protocols
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether Semax is appropriate for you.
- info
Removed from FDA Category 2 in 2026; final action on the 503A compounding list is pending — currently offered as educational information and waitlist only
- info
Not FDA approved in the United States
- info
Should be coordinated with any existing psychiatric care
Related peptides
More from the Cognitive category
This compound is pending FDA compounding review.
We don't dispense it today. Join the waitlist and we'll notify you if it becomes available through our licensed pharmacy partners.